The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

New mobile app helps doctors find clinical trials for cancer patients

Friday, June 01, 2012

New mobile app helps doctors find clinical trials for cancer patients09:00 EDT Friday, June 01, 2012Lilly Oncology also launches new website with detailed pipeline informationINDIANAPOLIS, June 1, 2012 /PRNewswire/ -- Today, Eli Lilly and Company (NYSE: LLY) launched a searchable clinical trial mobile application for oncology healthcare professionals. The app ? available for Apple iPad and iPhone, as well as RIM's BlackBerry and Google's Android platforms ? allows healthcare professionals to search oncology trials that are enrolling new patients by disease state, molecule being studied, study phase, country, state and keyword. Because the mobile app provides details on all global oncology trials, the app's functionality also provides a mechanism for the healthcare professional to contact Lilly Oncology for additional details on its trials, as well as a third-party contact for the non-Lilly clinical trials."Lilly Oncology created the Clinical Trial Resource mobile app to offer cancer care professionals an easy way to search for and identify details about all global oncology clinical trials ? not just those sponsored by Lilly," said Anne White, senior director of portfolio management with Lilly Oncology. "The information will enable physicians to provide the most current study information ? quickly ? to patients who may be interested in participating in a clinical trial."Clinical trial app available on new Lilly Oncology websiteDirections for downloading the clinical trial app are available on a new website, LillyOncologyPipeline.com, an online resource that will house information on its pipeline of potential cancer and supportive care molecules. At LillyOncologyPipeline.com, healthcare professionals can search for information about Lilly Oncology's pipeline by drug discovery platform, cancer type, clinical trial phase and molecular target. Specific information about each medicine includes illustrations of the target pathway and, when available, video of the pipeline compound's method of action."With LillyOncologyPipeline.com, the healthcare professional will now have immediate access to detailed information on our diverse oncology pipeline," added White. "We hope that this will foster not only greater awareness of our potential medicines, but also spark innovative collaborations that ultimately change the world of cancer care."Note: The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.About Lilly OncologyFor more than four decades, Lilly Oncology, a division of Eli Lilly and Company, has been dedicated to delivering innovative solutions that improve the care of people living with cancer.  Because no two cancer patients are alike, Lilly Oncology is committed to developing novel treatment approaches. To learn more about Lilly's commitment to cancer, please visit www.LillyOncology.com.   About Eli Lilly and CompanyLilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers ? through medicines and information ? for some of the world's most urgent medical needs. P-LLY This press release contains forward-looking statements about a searchable clinical trial mobile application for oncology healthcare professionals. It reflects Lilly's current beliefs; however, these statements involve risks and uncertainties and actual results may differ.  For example, the application is dependent on third-party content and there is no guarantee that the application will be utilized as anticipated or provide the expected results. For further discussion of risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.(Photo: http://photos.prnewswire.com/prnh/20120601/DE16867 )(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )SOURCE Eli Lilly and CompanyFor further information: Amy Sousa, Lilly, +1-317-276-8478 (office), +1-317-997-1481 (mobile), sousa_amy_e@lilly.com; or Neil Hochman, TogoRun, +1-212-453-2067 (office), +1-516-784-9089 (mobile), n.hochman@togorun.net